138 results about "Tumor recurrence" patented technology

The invention discloses a tumor recurrence risk prediction method and system based on electronic medical record data, and relates to the field of electronic medical record data processing and analys.The historical electronic medical record data are processed in a structured mode, a recurrence risk mapping model is established, individualized recurrence risk assessment can be achieved based on multi-dimensional features, and the tumor recurrence risk prediction accuracy is improved. The subjective judgment error is obviously reduced; a risk level layering mechanism can automatically distinguish patients needing emergency intervention and conventional monitoring, excessive medical treatment or delayed treatment is avoided, and the method is particularly suitable for chronic diseases such as tumors needing long-term management; through periodic marker measurement and risk level feedback, closed-loop management of evaluation-intervention-re-evaluation is formed, and the requirement for continuous optimization of clinical diagnosis and treatment is met; in addition, through preprocessing, the preprocessed multi-dimensional features can be directly called subsequently, and repeated data cleaning work is avoided.

The invention discloses a zinc-selenium doped white calcium stone injectable hydrogel for treating melanoma and a preparation method of the zinc-selenium doped white calcium stone injectable hydrogel. The preparation method comprises the following steps: 1, preparing hydrophilic zinc-selenium doped white calcium stone; 2, preparing oxidized sodium alginate; and (3) dispersing the hydrophilic zinc-selenium-doped white phosphorus calcium stone into the oxidized sodium alginate solution, adding the carboxymethyl chitosan solution, and uniformly mixing to obtain the zinc-selenium-doped white phosphorus calcium stone injectable hydrogel for treating melanoma. The injectable hydrogel prepared by the invention has good injectability, self-healing property and biocompatibility, and is suitable for tumor wound models with any shape and depth; the composition has good effects of promoting normal cell proliferation and inhibiting tumor cell growth, and can be used for tumor postoperative treatment to inhibit tumor recurrence and promote surgical defective tissue repair.

A computer implemented method of distinguishing tumor progression from treatment-related necrosis in digital images of a subject implements a multimodal deep learning architecture from MRI data of a selected anatomical portion of the subject, such as a brain, and corresponding dPET data for the subject with a tracer applied to the anatomical portion of the subject. The computer stores co-registered MRI data frames with dPET data frames as three dimensional (3D) parametric PET maps to identify multi-modal image features of segmented tumor data. A convolutional neural network uses MRI data and selected multi-modal image features as inputs and the computer concatenates respective output latent feature vectors from the respective sections of the at least one CNN. Feeding concatenated feature vectors to fully connected layers of the multimodal architecture distinguishes tumor progression from treatment-related necrosis of the anatomical portion of the subject.

The application provides a radionuclide nanohydrogel microneedle and a preparation method and application thereof, and belongs to the field of nanobiomedicine. 32 P-labeled calcium phosphate, which is formed by a biomimetic reaction of Ag2S@Ca 32 P nanoparticles, and a base layer which is a base matrix and comprises hyaluronic acid 32 P nanohydrogel microneedle can release Ag2S nanoparticles in response to a weakly acidic tumor environment, and under the irradiation of near-infrared light, the photothermal conversion efficiency can effectively kill bacteria, effectively improve the tumor hypoxic environment, enhance the treatment effect of radionuclides, play an antibacterial and wound healing promoting role in melanoma defect repair, and maximize the inhibition of tumor growth and tumor recurrence.

The invention relates to the technical field of biomedical engineering and drug delivery, and particularly discloses a novel targeted drug delivery system based on rose fruit extracellular vesicles, which comprises the following steps: preparing rose fruit source extracellular vesicles; preparing a medicine carrying vesicle; preparing targeted modified drug-loaded vesicles; according to the application disclosed by the invention, a stem related pathway is specifically down-regulated through the components of the rose fruits, and meanwhile, conventional tumor cells are killed by using adriamycin, so that a complementary treatment mechanism is formed, and the tumor recurrence risk is fundamentally reduced. The phenylboronic acid group of DSPE-PEG-PBA is used for specifically recognizing sialic acid over-expressed on the surface of a tumor cell, so that the enrichment of the medicine in tumor tissues is remarkably improved, and meanwhile, the distribution of normal tissues is reduced. By means of the natural biocompatibility and low immunogenicity of the RHNVs and in combination with the long circulation characteristic of a PEG chain, the delivery efficiency is guaranteed, the systemic toxicity is reduced to the maximum extent, and particularly the cardiotoxicity and myelosuppression of adriamycin are relieved.

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

The present disclosure relates to chimeric antigen receptor cells targeting ROBO1, in particular, enhanced CAR-T cells and CAR-NK cells targeting ROBO1, and preparation and application thereof. The cells can stably expressing CAR elements, while secreting extracellular domain molecules expressing PD-1 protein or mutants thereof, and thus may block PD-11PD-L1 molecular interaction. It has been found through animal experiments that the cells have very good anti-tumor effects, and the above-mentioned cells can significantly reduce tumor recurrence and improve the survival rate compared with the conventional ROBO1-targeted CAR modified cells.

The invention discloses a manganese urate material, a gel preparation and application thereof, and relates to the technical field of gel preparations. The manganese urate material provided by the invention can enhance anti-tumor immune response, and has good application prospects of adjuvants, vaccines and medicines. Besides, the invention also provides a gel preparation, the preparation is a multifunctional temperature-sensitive hydrogel preparation taking poloxamer as a matrix, and the preparation is combined with artesunate, adriamycin, uric acid and manganese to realize efficient treatment of various tumors such as breast cancer and inhibit postoperative recurrence of the tumors.

The application discloses a tumor recurrence risk prediction method and system based on electronic medical record data, relates to the field of electronic medical record data processing and analysis, and can realize individualized recurrence risk assessment based on multidimensional characteristics, significantly reduces subjective judgment errors, and establishes a recurrence risk mapping model through structured processing of historical electronic medical record data; a risk grade stratification mechanism can automatically distinguish patients who need emergency intervention from patients who need routine monitoring, avoids excessive medical treatment or delayed treatment, and is especially suitable for chronic diseases such as tumors that need long-term management; through periodic marker measurement and risk grade feedback, a closed-loop management of 'assessment-intervention-reassessment' is formed, meeting the needs of continuous optimization of clinical diagnosis and treatment; in addition, through preprocessing, multidimensional characteristics after preprocessing can be directly called in the subsequent process, and repeated data cleaning work is avoided.

The invention provides a tumor radiotherapy rehabilitation abnormity early warning method and system, and relates to the technical field of medical data analysis, and the method comprises the steps: obtaining a first tumor CT image and first image feature information thereof, first focus region detection information and first focus feature information after the first reexamination after tumor radiotherapy treatment; and after the kth review, obtaining a second tumor CT image and second image feature information thereof, and obtaining second focus area detection information and second focus feature information in combination with the first focus feature information so as to determine abnormal early warning information. According to the method and the device, the tumor CT image obtained after each review can be processed by using the anomaly recognition model, and during processing, the tumor CT image obtained during the previous review is combined for comprehensive analysis, and the condition and change of a focus can be analyzed, so that the comprehensiveness and the accuracy of analysis are improved, the distinguishing accuracy of pseudomorphism and tumor recurrence is improved, and the success rate of tumor review is improved. And the early warning accuracy is improved.

This invention relates to the field of biotechnology, specifically to a TruC-T cell that secretes and expresses IL-7 and PF4 to enhance anti-tumor activity and targets uPAR, and its application. Interleukin-7 (IL-7) can effectively promote the development, survival, and proliferation of T cells, while platelet factor 4 (PF4 / CXCL4) can regulate the immune response and chemotactically attract leukocytes to specific sites; the synergistic effect of the two can enhance the anti-tumor function and persistence of T cells. Meanwhile, urokinase-type plasminogen activator receptor (uPAR) is highly expressed in various solid tumors and hematological malignancies, making it an ideal target for tumor therapy; TruC-T cells targeting uPAR can precisely act on tumor tissue, and combined with the immune-enhancing effects of IL-7 and PF4, can significantly improve the efficacy of anti-tumor immune responses, prolong the duration of therapeutic effects, and reduce tumor recurrence.

The application discloses a novel AIE photosensitizer and a preparation method and application thereof. The AIE photosensitizer of the application comprises TDQ shown in the following structural formula, has superior photo-thermal conversion performance and photodynamic performance, and can be used for preparing a tumor diagnosis reagent or a tumor treatment drug. The co-loading liposome of TDQ and a senescence-inducing molecule (Ali) can be used as a multi-modal light diagnosis and treatment agent to realize efficient delivery of drugs to tumor tissues, and the photo-thermal therapy and the photodynamic therapy based on TDQ not only induce cell apoptosis through oxidative stress and mitochondrial dysfunction, but also trigger cancer cell senescence and promote the secretion of SASPs, so that the anti-tumor immunity is significantly enhanced, and finally the growth of primary tumors, tumor recurrence and re-metastasis are inhibited. The material of the application has simple preparation process, low cost, and is suitable for scale production and clinical medical use.

The invention belongs to the technical field of biological medicine, and particularly relates to application of an anti-HIV drug in inhibition of non-small cell lung cancer drug resistance. The invention finds that the combined use of the anti-HIV drug and EGFR-TKI can effectively and specifically target the MRD drug-resistant cells, inhibit the formation of the MRD drug-resistant cells, significantly improve the curative effect of EGFR-TKI and delay tumor recurrence.

The present invention relates to an oncolytic adenovirus capable of co-expressing interleukin-12 and a C-met-inhibiting oligonucleotide; and an antitumor immune-boosting composition and anticancer composition comprising the oncolytic adenovirus. The present invention has first identified an adenovirus system having simultaneous effects of IL-12 expression and C-met inhibition in cancer gene treatment. The adenovirus system of the present invention is capable of inhibiting C-met while expressing interleukin-12, thereby restoring immune functions in a tumor environment to enhance anticancer effects such as the inhibition of tumor recurrence and tumor growth and to inhibit tumor migration. Accordingly, the adenovirus system of the present invention can be effectively used in the treatment of cancer.

The application discloses a bispecific chimeric antigen receptor targeting HER2 and HLA-G and application thereof, and belongs to the tumor immunotherapy field.The chimeric antigen receptor comprises an extracellular domain, a hinge domain, a transmembrane domain and at least one intracellular domain, and the extracellular domain comprises an anti-HER2 single-chain antibody and an anti-HLA-G single-chain antibody.The bispecific chimeric antigen receptor of the application can effectively improve the killing signal of immune cells, and can effectively avoid the inhibition of the immunosuppressive signal on the function of immune cells, thereby delaying the recurrence of tumors, and has very important clinical application value.

A pharmaceutical composition comprises an oncolytic virus and odontogenic stem cells. At least a portion of the oncolytic virus is contained within the odontogenic stem cells. The pharmaceutical composition treats tumors, prevents tumor recurrence or inhibits tumor metastasis through intraperitoneal administration and intratumor injection.

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

The application belongs to the technical field of biomedical materials, and discloses a acutine-chitosan / calcium carbonate hemostatic sponge as well as a preparation method and application thereof. The acutine and chitosan are condensed to obtain acutine-chitosan, and then the acutine-chitosan is reacted with sodium carbonate, calcium hydroxide and urea to form the acutine-chitosan / calcium carbonate hemostatic sponge. In-vivo and in-vitro experiments verify that the sponge can be used for hemostasis and antibiosis, and due to the pH sensitivity of the acutine-chitosan, the acutine can be intelligently controlled to be released under acidic conditions (cancer acidic environment), so that the sponge can be used for rapid hemostasis during cancer surgery, and also helps to prevent recurrence of liver cancer after surgery. Therefore, the multifunctional acutine-chitosan / calcium carbonate hemostatic sponge of the application provides a 'one-stop' synergistic strategy for intraoperative hemostasis and postoperative prevention of tumor recurrence of liver cancer, and has great clinical application potential.

The application provides a magnetic response composite hydrogel for integrated repair of bone defects and a preparation method thereof, and belongs to the technical field of medical materials. The composite hydrogel can efficiently inhibit tumor cell activity under the time sequence regulation of an external alternating magnetic field, and then provide a suitable microenvironment and key components for bone tissue regeneration, so that signal conversion and function connection from tumor killing to bone repair are realized. The material has good injectability and self-healing ability, can minimally invasively fill irregular defects, and has significant advantages in simplifying the clinical treatment procedure, shortening the treatment course, reducing the risk of tumor recurrence and improving the repair quality, and provides a new and integrated treatment strategy for tumor-related bone defects.

The invention belongs to the technical field of biological detection and treatment, and particularly relates to an innovative application of novel circRNA: circM-TMEFF1 in diagnosis and treatment of hepatocellular carcinoma. The circM-TMEFF1 forms a ring in hepatocellular carcinoma cells, and the specificity of the circM-TMEFF1 is in low expression. The invention specifically provides application of circM-TMEFF1 as a marker in preparation of a hepatocellular carcinoma diagnosis or prognosis kit, and compared with a normal control person, the expression quantity of circM-TMEFF1 in hepatocellular carcinoma tissues and tumor recurrent tissues is remarkably reduced, so that circM-TMEFF1 can be used as a biomarker for diagnosis and prognosis of hepatocellular carcinoma. Besides, promotion of circM-TMEFF1 expression can effectively inhibit proliferation and growth of hepatocellular carcinoma cell lines, a new target is provided for improvement of treatment of hepatocellular carcinoma, and the circM-TMEFF1 has great clinical value.

The invention provides a personalized cancer vaccine based on apoptosis vesicles and a preparation method and application thereof, and belongs to the technical field of biological medicine, the personalized cancer vaccine comprises apoptosis vesicles, an immunologic stimulant and a biocompatibility carrier; the apoptosis vesicles are extracellular vesicles generated after tumor cells are subjected to apoptosis induction; the biocompatible carrier is a modified chitosan hydrogel, and the biocompatible carrier is a modified chitosan hydrogel; the immunologic stimulant is loaded in the apoptosis vesicle, and the apoptosis vesicle loaded with the immunologic stimulant is embedded into the modified chitosan hydrogel. According to the invention, apoptosis vesicles generated by induction of tumor cells of a patient are taken as a core, the apoptosis vesicles have a natural tumor antigen library and a strong immune activation capability, and personalized precise treatment can be realized; meanwhile, the invention provides a preparation method and application in postoperative tumor recurrence prevention and treatment, and provides technical support for clinical transformation.

The invention provides a degradable flexible electronic device which is applied to tumor postoperative monitoring and comprises a substrate layer, an electrode layer, an electrode modification layer and a packaging layer. The electrode layer is formed on the substrate layer in a patterned structure and forms a plurality of groups of electrode arrays, and a working electrode is configured in each group of electrode array; the electrode modification layers are located on all the working electrodes, aptamers are assembled in the electrode modification layers, and the electrode modification layers are used for being in targeted combination with tumor target markers in the to-be-monitored area after the tumor operation and reacting, changing the interface impedance of the working electrodes and transmitting interface impedance signals of the working electrodes to an external receiving device; the external receiving device monitors the interface impedance signal state based on the interface impedance signal of the working electrode so as to obtain information about whether tumor recurrence and / or metastasis exist in the to-be-monitored area after the tumor operation; the substrate layer, the electrode layer and the packaging layer are all made of degradable materials. The invention further provides a preparation method of the degradable flexible electronic device and a monitoring system.

The application belongs to the technical field of cell engineering, and particularly relates to a bispecific antibody targeting CD22 and CD19, a chimeric antigen receptor thereof and application. In the bispecific antibody, a CD22 light chain and a CD22 heavy chain are connected through a linker 4 to form a CD22 single-chain antibody, and a CD19 light chain and a CD19 heavy chain are connected through a linker 4 to form a CD19 single-chain antibody, which comprises one of the following structures: (1) the CD22 single-chain antibody and the CD19 single-chain antibody are connected through a linker 1 or a liner 2; (2) the two ends of the CD19 single-chain antibody are connected with the CD22 light chain and the CD22 heavy chain through a linker 3, respectively. The chimeric antigen receptor provided by the application can simultaneously target two different tumor antigens, improve the killing of tumor cells, reduce the probability of immune escape, and reduce the tumor recurrence rate after CAR-T treatment.

The invention discloses an FGF2 inhibitor composition of a targeted iCAFs subgroup and application of the FGF2 inhibitor composition in bladder cancer prevention and treatment, and relates to the technical field of FGF2 inhibitor compositions of targeted iCAFs subgroups, the FGF2 inhibitor composition is used for preparing a medicine for bladder cancer prevention and treatment, the composition comprises an FGF2 inhibitor, and the FGF2 inhibitor can inhibit the bladder cancer by inhibiting interaction between FGF2 secreted by ICAM1 + iCAFs and tumor stem cell surface CD44, so that the bladder cancer can be prevented and treated, and the bladder cancer can be prevented and treated. According to the application disclosed by the invention, ICAM1 + inflammatory cancer related fibroblast iCAFs subpopulation in a bladder cancer recurrence related tumor microenvironment is targeted, a fibroblast growth factor FGF2 signal secreted by the ICAM1 + inflammatory cancer related fibroblast iCAFs subpopulation is specifically inhibited, the dependency support of the tumor microenvironment on the stemness maintenance of the tumor stem cells is destroyed, and the stemness maintenance of the recurrence related tumor stem cell subpopulation is inhibited. Therefore, the biological basis of tumor recurrence and progression is weakened from the source.

The invention belongs to the technical field of biological medicine, and particularly relates to a co-load bionic whole-tumor vaccine as well as a preparation method and application thereof. The preparation method comprises the following steps: preparing fungal cell wall nanoparticles, preparing dead tumor cells and synthesizing the coupled vaccine. The invention discloses a co-load bionic whole-tumor vaccine, which breaks through the expression limitation of natural antigens, and enhances an immunogenicity activation signal through artificial modification. Immune cells are activated in a targeted manner through fungal cell wall components, so that the antigen presentation efficiency is remarkably improved. The compound can be applied to preparation of medicines for preventing and treating tumor diseases or medicines for inhibiting tumor recurrence or metastasis. The invention also discloses a preparation method of the co-loaded bionic whole-tumor vaccine, the preparation process is simplified, and the process complexity is reduced by using a standardized coupling technology of microorganisms and tumor cells.

The invention belongs to the technical field of probiotic preparations, and particularly relates to engineered probiotics loaded with Cu2-xSe nanoparticles in cells as well as a preparation method and application of the engineered probiotics. According to the application, the non-toxic probiotics are used as a bioreactor, and the engineered probiotics which are good in stability and have excellent photo-thermal performance and H2O2 catalysis performance and are loaded with the Cu2-xSe nanoparticles in cells are successfully constructed by regulating and controlling incubation conditions of the probiotics, the copper source and the selenium source. The compound can enrich tumor sites in a targeted manner, is efficiently taken by tumor cells, kills the tumor cells, induces M2 type TAMs to be reversely polarized into M1 type TAMs, improves inhibitory TIME, promotes TDLNs and DCs in TME to be mature, increases infiltration of CD8 + effector T cells and the number of CD8 + T cells and central memory T cells in the spleen, and achieves the anti-tumor effect. In addition, the long-term immune memory effect can be induced to be generated, and tumor recurrence is effectively inhibited.

The application belongs to the technical field of drug delivery carrier, and particularly relates to a dual-metal nanodot-oncolytic virus intravenous delivery system and a preparation method and application thereof in tumor immunotherapy. The oncolytic adenovirus is used as raw material, and the dual-metal nanodot-adenovirus chimera is constructed by using the covalent force of 4-maleimide butyric acid-N-succinimidyl ester. The preparation performance, cytotoxicity, action mechanism, in-vivo anti-tumor effect, anti-tumor immunity, anti-tumor recurrence and anti-tumor metastasis effect of the chimera are evaluated. The preparation process is simple, the prepared dual-metal nanodot-adenovirus chimera has small and uniform particle size, is conducive to enrichment in tumor tissues through the enhanced permeability and retention (EPR) effect, has high drug loading capacity, good safety and can generate high-intensity MRI signals at the tumor site. The designed dual-metal nanodot-adenovirus chimera realizes the integration of tumor diagnosis and treatment.

A wearable device (1) for treating cancer cells by mechanical stimulation of a patient's surface tissue, in particular skin, subcutaneous tissue or mammary gland, wherein the device (1) comprises: a support element (2) applicable to the patient's tissue; and stimulation and control means (3) connected to the support element (2) wherein the stimulation and control means (3) comprise: at least one actuator (4) for delivering the mechanical stimulation at at least one stimulation point (5); at least one sensor (6) for detecting a physical property at the tissue of the patient to be treated and for generating a corresponding sensor signal; and a control unit (7) connected to the actuator (4) and to the sensor (6), the control unit (7) for regulating the movement of the actuator (4) by a control signal in dependence on said at least one sensor signal, in which the mechanical stimulation is transmitted by the actuator (4) to the stimulation point (5) in order to deform the tissue to be treated in dependence on a periodic trend, especially the contraction and relaxation of the tissue.

The invention discloses a traditional Chinese medicine composition for treating tumors caused by internal stagnation of toxic blood stasis. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 47-49 parts of longpimpinella pedicularis, 24-26 parts of black ants and 24-26 parts of toad skin. According to the invention, only the three medicinal materials, namely Longdiland, black ant and toad skin, are adopted, the formula is simple, the medicinal materials are wide in source and controllable in cost, the pharmacological actions of the three medicinal materials are complementary, Longdiland enhances immunity and resists inflammation, black ant regulates immunity, resists inflammation and relieves pain, toad skin directly plays an anti-tumor role, the effects of attacking hard mass, breaking stasis, resisting cancer and diminishing swelling are realized, and a precise formula is prepared aiming at the pathogenesis of internal stagnation of toxic blood stasis; clinical verifications prove that the traditional Chinese medicine can effectively relieve clinical symptoms of tumors caused by internal accumulation of toxic stasis and control recurrence and metastasis of the tumors; meanwhile, the body immunity of patients is improved, the life quality is improved, the survival time is prolonged, and compared with existing partial traditional Chinese medicine preparations, the curative effect is clearer, and the pertinence is higher. The invention further discloses a preparation method of the traditional Chinese medicine composition.